Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies

Ping-Pin Zheng; Johan M Kros; Guanyu Wang

doi:10.1016/j.it.2019.02.005

Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies

Trends Immunol. 2019 Apr;40(4):274-278. doi: 10.1016/j.it.2019.02.005. Epub 2019 Mar 12.

Authors

Ping-Pin Zheng¹, Johan M Kros², Guanyu Wang³

Affiliations

¹ Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen, Guangdong, China; These authors contributed equally to this work. Electronic address: zhengpp@sustech.edu.cn.
² Department of Pathology, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, The Netherlands.
³ Department of Biology, Southern University of Science and Technology, Shenzhen, Guangdong, China; These authors contributed equally to this work. Electronic address: wanggy@sustech.edu.cn.

PMID: 30876815
DOI: 10.1016/j.it.2019.02.005

Abstract

Several T cell-boosting anticancer therapies (including anti-CD19 CAR-T cells and bi-specific T cell engagers, BiTEs) have been approved by the FDA for specific clinical indications. Their potency has been demonstrated in various clinical trials, but some life-threatening complications such as neurotoxicity remain poorly understood. Thus, by conducting multifaceted investigations, a better understanding of T cell immunotherapy-associated neurotoxicity to bridge the gap between basic research and clinical practice is urgently needed.

Keywords: BiTEs; CAR-T; CNS damage; T cell-boosting therapies; encephalopathy; neurotoxicity.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Humans
Neoplasms / drug therapy*
Neoplasms / immunology*
Neurotoxicity Syndromes / immunology*
T-Lymphocytes / immunology*

Substances

Antineoplastic Agents